Literature DB >> 272226

Anaphylactoid type reactions in two patients receiving high dose intravenous methotrexate.

N H Goldberg, J L Romolo, E H Austin, J Drake, S A Rosenberg.   

Abstract

Two patients recieving intravenous high dose methotrexate (MTX) and intracutaneous BCG injections as adjuvant treatment for osteogenic sarcoma suffered sudden cardiovascular collapse within minutes of infusion of MTX. These cases demonstrate that anaphylactic or idiosyncratic reactions to MTX and/or contaminants in these preparations do occur and that careful patient monitoring is required.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 272226     DOI: 10.1002/1097-0142(197801)41:1<52::aid-cncr2820410109>3.0.co;2-p

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  5 in total

1.  Survival after unexpected high serum methotrexate concentrations in a patient with osteogenic sarcoma.

Authors:  D J Grimes; M R Bowles; J A Buttsworth; D B Thomson; P J Ravenscroft; P F Nixon; R F Whiting; S M Pond
Journal:  Drug Saf       Date:  1990 Nov-Dec       Impact factor: 5.606

2.  Hypersensitivity reaction to high-dose methotrexate and successful rechallenge in a pediatric patient with osteosarcoma.

Authors:  Jeffrey R Scott; Deborah A Ward; Kristine R Crews; John C Panetta; Fariba Navid
Journal:  Pediatr Blood Cancer       Date:  2013-08-19       Impact factor: 3.167

3.  Hypersensitivity reactions to trimetrexate.

Authors:  J L Grem; S A King; M E Costanza; T D Brown
Journal:  Invest New Drugs       Date:  1990-05       Impact factor: 3.850

4.  Sensitization to low dose 5-fluorouracil. Subsequent enhancement of its systemic antitumor effect in the rat.

Authors:  R E Falk; M Hardy; L Makowka; J Teodorczyk-Injeyan; J A Falk
Journal:  J Clin Invest       Date:  1982-09       Impact factor: 14.808

5.  Study of histamine release induced by acute administration of antitumor agents in dogs.

Authors:  A Eschalier; J Lavarenne; C Burtin; M Renoux; E Chapuy; M Rodriguez
Journal:  Cancer Chemother Pharmacol       Date:  1988       Impact factor: 3.333

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.